Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Inozyme Pharma, Inc | Ongoing | INZ-701 | 3 | INZ701-105 | King Faisal Specialist Hospital and Research Center (Riyadh) | |
| Argenx BV | Ongoing | Efgartigimod IV | 4 | ARGX-113-2308 | King Faisal Specialist Hospital and Research Center (Riyadh) | |
| Hoffmann-La Roche Ltd | Completed | N/A | 4 | MO42921 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh) | |
| Eli Lilly | Ongoing | Tirzepatide | 4 | I8F-MC-GPIY | Al Moosa Specialized Hospital (al ahsa) ,Dallah Hospital (Riyadh) ,Saudi Airlines Medical Service Center (Jeddah), King Fahad Medical City (Riyadh) | |
| PI initiatied | Ongoing | Netupitant and palonosetron ,Granisetron transdermal patch, Ondansetron | 4 | 24-1205 | ||
| SK Plasma Co. | Ongoing | LIV-GAMMA SN Injection | 3 | SKP-LIV_PID_III_2023 | King Abdulaziz University Hospital (Jeddah) ,King Fahad Hospital (Jeddah), Al-Aziziyah Maternity and Children's Hospital | |
| Celgene Corporation | Ongoing | Golcadomide,BMS-986369 / CC-99282 | 3 | CA0731020 | King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam), King Abdullah Medical Complex (Jeddah) | |
| Real-World Evidence non-interventional prospective study for the effectiveness, tolerability and adherence of Asciminib after two previous TKIs in Patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) in Saudi Arabia. (ASC4REAL) | Novartis | Ongoing | Scemblix (Asciminib/ ABL001) | 4 | CABL001ASA | King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah), King Fahad Specialist Hospital (Dammam) |
| Boehringer Ingelheim | Ongoing | BI 1015550 | 3 | 1305-0031 | King Abdulaziz Medical City NG (Riyadh) | |
| ational, Registry of Patients with Anti-Aquaporin 4 Antibody-Positive (AQP4+) Neuromyelitis Optica Spectrum Disorder (NMOSD) Treated with Alexion Complement Component 5 (C5) Inhibitor Therapies (ALXN-C5IT) | Astrazeneca | Ongoing | Ultomiris (Ravulizumab) | 4 | ALX-NMO-50 | King Khalid University Hospital (Riyadh) ,King Abdulaziz Medical City NG (Jeddah),King Abdulaziz Medical City NG (Riyadh) |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.